The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final result of a phase I study of combination of pasireotide (SOM 230) LAR plus gemcitabine in metastatic pancreatic cancer (MPC).
Yaman Suleiman
No relevant relationships to disclose
Gregory M. Springett
No relevant relationships to disclose
Erin M. Siegel
No relevant relationships to disclose
David Shibata
No relevant relationships to disclose
William J. Fulp
No relevant relationships to disclose
Richard D. Kim
No relevant relationships to disclose